Trial Information

Summary: Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

A medical research study is underway for women who are concerned about their decreased sexual desire.  For many women, decreased sexual desire is often an unfortunate consequence of menopause and can lead to feelings of unhappiness, concern and frustration and can impact a woman’s relationship with her partner.  Hypoactive Sexual Desire Disorder (HSDD) is the most common form of female dysfunction.  The condition is typically identified by decreased or absent sexual fantasies and desire for sex - and the exact cause is unknown. 

Compensation: Eligible patients will receive up to $450.00

Study Description: The purpose of this study is to assess the safety and efficacy of LibiGel applied daily for 6 months compared to placebo treatment of HSDD in healthy, surgically menopausal women taking estrogen.

Inclusion Criteria

• Woman 30 to 65 years of age
• Undergone hysterectomy and bilateral oophorectomy prior to natural menopause
• Taking estrogen therapy for at least 3 months
• In a stable relationship for at least 1 year that is secure and communicative

Additional inclusion and exclusion criteria apply and will be reviewed with you.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.